Product Description

🔹 Product Overview
ELIGARD 45 mg Injection is a hormone therapy medicine used for the treatment of advanced prostate cancer. It contains Leuprolide Acetate 45 mg, a Gonadotropin-Releasing Hormone (GnRH) agonist that works by reducing testosterone levels in the body. Since prostate cancer cells often depend on male hormones for growth, lowering testosterone helps slow the progression of hormone-sensitive prostate cancer.

🔹 Key Uses
Treatment of advanced prostate cancer
Hormone therapy for androgen-dependent prostate cancer
Helps reduce testosterone stimulation of prostate cancer cells
Supports disease management as part of androgen deprivation therapy (ADT) under specialist care

🔹 Composition
Active Ingredient: Leuprolide Acetate 45 mg
Drug Class: Gonadotropin-Releasing Hormone (GnRH) Agonist
Dosage Form: Extended-release subcutaneous injection

🔹 How It Works

ELIGARD 45 mg works by initially affecting GnRH activity and, with continuous administration, suppressing the release of hormones responsible for testosterone
production. This leads to a significant reduction in testosterone levels, helping slow the growth and progression of hormone-sensitive prostate cancer cells.

🔹 Key Benefits
Provides long-acting hormone therapy for prostate cancer
Helps lower testosterone levels that support cancer cell growth
Convenient 6-month dosing schedule
Used as part of a specialist-guided prostate cancer treatment plan
Helps maintain continuous androgen suppression during therapy

🔹 Dosage and Administration
Administer only under the supervision of a qualified healthcare professional.
The recommended dose of ELIGARD 45 mg is administered once every 6 months.
Given as a subcutaneous injection.
Injection site may be varied according to medical guidance.
Regular follow-up, including PSA and hormone level monitoring, may be recommended by the treating physician.

🔹 Possible Side Effects
Common side effects may include:
Hot flashes
Increased sweating
Fatigue
Decreased sexual desire
Erectile dysfunction
Injection site reactions
Weight changes
Mood changes
Bone density reduction with long-term androgen deprivation therapy
Seek medical advice promptly if you experience severe allergic reactions, chest pain, unusual weakness, or symptoms of serious complications.

🔹 Precautions
Use only under an oncologist’s or specialist’s supervision.
Inform your doctor if you have a history of heart disease, diabetes, osteoporosis, or metabolic disorders.
Regular monitoring may be required during long-term treatment.
Discuss all medicines, supplements, and existing health conditions with your doctor.
Do not stop treatment without medical advice.
Treatment decisions should be based on individual cancer status and medical evaluation